In our clinical material, the BCT intervention was most frequently possible in patients with luminal A breast cancer (62.9% of analyzed cases), while BCT was the least frequently performed in patients diagnosed as HER2-positive (3.8% of women qualified for the study). Here, ERBB2 is linked to breast cancer.